Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs in Metastatic or Recurrent Cervical Cancer
NCT04674488Phase 1Unknown
- Sponsor
- OriCell Therapeutics
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MDA-TIL in Cervical Cancer (CC), sponsored by OriCell Therapeutics. Primary endpoint: Dose Limited Toxicity at 28 days. Status: unknown.
02
Drugs
MDA-TIL
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04674488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674488.